TriangleNCT01973062 · OUTCOME
Radiographic Response Assessed by MRI or FDG-PET/MRI
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- Not reported
- Unit
- Not reported
- Interval / dispersion
- Not reported
- Time frame
- Up to 2 years
What was measured
Number of patients with at least a 50% reduction in tumor size on a MRI scan with stable or decreasing dose of corticosteroids
Analysis population: Only one patient registered. No patient data analyzed
Groups in this outcome
Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan
Patients receive rituximab IV on day 1. Within 7 to 9 days, patients receive rituximab IV and yttrium Y 90 ibritumomab tiuxetan IV in the absence of disease progression or unacceptable toxicity. rituximab: Given IV yttrium Y 90 ibritumomab tiuxetan: Given IV
| Group | Source count |
|---|---|
| Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan | 0 |
Reported measurements
No numerical measurement classes were posted for this outcome. Missing is not zero.
Complete source fields
- denoms
- counts
- group Id
- OG000
- value
- 0
- units
- Participants
- description
- Number of patients with at least a 50% reduction in tumor size on a MRI scan with stable or decreasing dose of corticosteroids
- groups
- description
- Patients receive rituximab IV on day 1. Within 7 to 9 days, patients receive rituximab IV and yttrium Y 90 ibritumomab tiuxetan IV in the absence of disease progression or unacceptable toxicity. rituximab: Given IV yttrium Y 90 ibritumomab tiuxetan: Given IV
- id
- OG000
- title
- Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan
- population Description
- Only one patient registered. No patient data analyzed
- reporting Status
- POSTED
- time Frame
- Up to 2 years
- title
- Radiographic Response Assessed by MRI or FDG-PET/MRI
- type
- PRIMARY
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice